How to buy Janssen shares | $N/A

A subsidiary of Johnson & Johnson, Janssen is a Belgian pharmaceutical company which announced in January 2021 that its single-dose COVID-19 vaccine is 66% effective. As a single-dose jab, the vaccine would be easier to roll out than existing vaccines, and could help boost the international vaccination effort. While the vaccine has yet to be approved by regulators, the UK has already pre-ordered 30 million doses.

Janssen Pharmaceuticals is a pharmaceutical company that researches medical disorders, such as mental illness, neurological disorders and gastrointestinal disorders, for the development of new drugs. Janssen is one of the companies that has created a vaccine for COVID-19, having received $456 million (£342 million) from the U.S. Biomedical Advanced Research and Development Authority.

It’s possible to invest in Janssen Pharmaceuticals, but as it’s owned by Johnson & Johnson, you’d need to buy Johnson & Johnson shares.

What other brands does Johnson & Johnson own?

Johnson & Johnson owns some really recognisable brands here in the UK, including:

• Tylenol medication
• Johnson’s Baby products
• Neutrogena
• Clean & Clear
• Acuvue

This means that if you choose to invest in Janssen by buying shares in Johnson & Johnson, then you’ll be investing in the other brands that it owns as well. Research all of the brands above and other brands that Johnson & Johnson owns to get a full picture of the company.

Can I buy Janssen shares?

While you can't invest directly in Janssen, you can buy Johnson & Johnson shares, which is the company that owns Janssen. Johnson & Johnson is listed on the NYSE with stock code JNJ.US the current share price is $N/A (25 minute delay).

Janssen is owned by Johnson & Johnson (JNJ) a leading Pharmaceuticals business based in the USA. It opened the day at $N/A, after a previous close of $N/A. During the day the price has varied from a low of $N/A to a high of $N/A. The latest price was $N/A (25 minute delay). Janssen (JNJ) is listed on the NYSE and employs 131900 staff. All prices are listed in US Dollar.

How to buy shares in Janssen

1. Choose a share-dealing platform. If you’re a beginner, our table below can help you choose.
2. Open your account. You’ll need your ID, bank details and national insurance number.
3. Confirm your payment details. You’ll need to fund your account with a bank transfer, debit card or credit card.
4. Search the platform for stock code: JNJ in this case.
5. Research Janssen (Johnson & Johnson) shares. The platform should provide the latest information available.
6. Buy your Janssen (Johnson & Johnson) shares. It's that simple.

• Janssen (Johnson & Johnson) live prices
• Janssen (Johnson & Johnson) profile

Janssen (Johnson & Johnson) share price

Use our graph to track the performance of JNJ stocks over time.

Invest in shares with 0% commission on eToro

Finder Award

• Start investing from $100
• Join 30 million users who trust their investments with eToro

Go to site

Capital at risk

Other fees may apply

All investing should be regarded as longer term. The value of your investments can go up and down, and you may get back less than you invest. Past performance is no guarantee of future results. If you’re not sure which investments are right for you, please seek out a financial adviser. Capital at risk.

Compare share dealing platforms

Why invest in Janssen?

Janssen was founded in 1953 and has produced a huge range of drugs, including 8 that are included in the World Health Organisation’s Model List of Essential Medicines. It’s one of the companies that’s created a vaccine against coronavirus, which has been approved in several countries, including the UK.

Johnson & Johnson owns some of the most recognisable brands in the healthcare aisle in the supermarket. If you’re umming and ahhing between two facial washes, there’s a pretty good chance they’re both made by Johnson & Johnson.

An overview of Johnson & Johnson the parent company of Janssen

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. Its MedTech segment provides Interventional Solutions, including electrophysiology products to treat heart rhythm disorders; the heart recovery portfolio, which includes technologies to treat severe coronary artery disease requiring high-risk PCI or AMI cardiogenic shock; and neurovascular care that treats hemorrhagic and ischemic stroke. this segment also offers an orthopaedics portfolio that includes products and enabling technologies that support hips, knees, trauma, spine, sports, and other; surgery portfolios comprising advanced and general surgery technologies, as well as solutions for breast aesthetics, ear, nose, and throat procedures; contact lenses under the ACUVUE Brand; and TECNIS intraocular lenses for cataract surgery. It distributes its products to wholesalers, hospitals, and retailers, as well as physicians, nurses, hospitals, eye care professionals, and clinics. The company has a collaboration agreement with Stand Up To Cancer for research testing a combination of teclistamab and daratumumab to treat a rare disease AL amyloidosis. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.

Frequently asked questions

• Who is the CEO of Johnson & Johnson?

  Alex Gorsky is the CEO of Johnson & Johnson.

• Who owns Janssen?

  Janssen Pharmaceuticals was acquired by Johnson & Johnson in October 1961.